Meeting
2024 ASCO Annual Meeting
A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.
Authors
Elise A. Chong
Lymphoma Program, Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
Elise A. Chong , Junichiro Yuda , Koji Izutsu , Luke Benjamin Fletcher , Wissam Assaily , Mohammad Sahtout , Mohamed Badawi , John M. Burke , James P. Dean , Claudina Stevenson , Christine Will , William G. Wierda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05753501
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS7091)
DOI
10.1200/JCO.2024.42.16_suppl.TPS7091
Abstract #
TPS7091
Poster Bd #
70a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2024 ASCO Annual Meeting
Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL).
First Author: Christian Grommes
Poster
2024 ASCO Annual Meeting
A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.
First Author: John C. Byrd
Poster
2024 ASCO Annual Meeting
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
First Author: Masa Lasica